DOCSLIB.ORG

Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation Neurotherapeutics https://doi.org/10.1007/s13311-019-00717-4 ORIGINAL ARTICLE Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation Pablo Villoslada 1 & Gemma Vila 1 & Valeria Colafrancesco 1 & Beatriz Moreno 1 & Begoña Fernandez-Diez 1 & Raquel Vazquez 1 & Inna Pertsovskaya 1 & Irati Zubizarreta 1 & Irene Pulido-Valdeolivas 1 & Joaquin Messeguer 2 & Gloria Vendrell-Navarro 2 & Jose Maria Frade 3 & Noelia López-Sánchez 3 & Meritxell Teixido 4 & Ernest Giralt 4 & Mar Masso 5 & Jason C Dugas 6 & Dmitri Leonoudakis 6 & Karen D. Lariosa-Willingham 6 & Lawrence Steinman 7 & Angel Messeguer 2 # The American Society for Experimental NeuroTherapeutics, Inc. 2019 Abstract The development of neuroprotective therapies is a sought-after goal. By screening combinatorial chemical libraries using in vitro assays, we identified the small molecule BN201 that promotes the survival of cultured neural cells when subjected to oxidative stress or when deprived of trophic factors. Moreover, BN201 promotes neuronal differentiation, the differentiation of precursor cells to mature oligodendrocytes in vitro , and the myelination of new axons. BN201 modulates several kinases participating in the insulin growth factor 1 pathway including serum –glucocorticoid kinase and midkine, inducing the phosphorylation of NDRG1 and the translocation of the transcription factor Foxo3 to the cytoplasm. In vivo , BN201 prevents axonal and neuronal loss, and it promotes remyelination in models of multiple sclerosis, chemically induced demyelination, and glaucoma. In summary, we provide a new promising strategy to promote neuroaxonal survival and remyelination, potentially preventing disability in brain diseases. Key Words Neuroprotection . neuroinflammation . neurodegenerative diseases . multiple sclerosis . glaucoma Introduction Brain diseases represent a significant clinical challenge due to Electronic supplementary material The online version of this article the known sensitivity of the central nervous system (CNS) to (https://doi.org/10.1007/s13311-019-00717-4 ) contains supplementary damage and its limited capacity for repair and regeneration. material, which is available to authorized users. Brain injury and brain diseases are notorious for significant long-term disability [ 1, 2]. After insult, damage to neurons and * Pablo Villoslada axons may induce several forms of neuropathology including [email protected] necrosis, apoptosis, autophagia, necroptosis, and pyroptosis. Further, brain injury may disrupt the connections between 1 Center for Neuroimmunology, Institut d ’Investigacions Biomediques neurons, as what occurs following axon degeneration (anter- August Pi Sunyer, Casanova 145, Centre Cellex 3A, ograde or Wallerian degeneration, retrograde degeneration or 08036 Barcelona, Spain dying-back, or even transynaptic degeneration), synaptic loss, 2 Institute for Advanced Chemistry of Catalonia, Consejo Superior de or dendritic pruning [ 3–5]. Although some of these processes Investigaciones Cientificas, Barcelona 08034, Spain take place early after insult, others may be delayed for weeks, 3 Instituto Cajal, Consejo Superior de Investigaciones Cientificas, months, or even years. For these reasons, the discovery of Madrid 28002, Spain agents that promote neuroprotection is a health priority. 4 Institute for Research in Biomedicine, Barcelona 08028, Spain In multiple sclerosis (MS), the autoimmune attack and 5 Bionure Farma SL, Barcelona 94025, Spain chronic inflammation produces a massive destruction of mye- 6 Myelin Repair Foundation, Saratoga, NY 94085, USA lin, with loss of oligodendrocytes and their precursors in the 7 Stanford University, Palo Alto, CA 94305, USA long term, as well as relative axonal loss. Long-term disability P. Villoslada et. al. is mainly dependent on axonal loss, which is the result of the PC12 cells were maintained in Dulbecco ’s modified acute inflammatory damage and degeneration of chronically Eagle ’s medium (DMEM) supplemented with 2.5% fetal bo- demyelinated axons. Because current immunotherapy de- vine serum (FBS), 15% horse serum (HS), and penicillin/ creases the frequency of autoimmune attacks but chronic in- streptomycin (P/S). The SH-SY5Y cell line was maintained flammation persists, neuroprotection is being pursued as com- in 50% Ham ’s F12 medium and 50% Earle ’s minimal essen- bination therapy to prevent high levels of disability [ 6]. On the tial medium, supplemented with 10% FBS, 2 mM L-gluta- other hand, glaucoma is a neurodegenerative disease of the mine, and 1% P/S. The NSC-34 cell line was cultivated in visual pathway, with high intraocular pressure being 1 of the DMEM with 10% FBS and 1% P/S. The rat Schwannoma most common predisposing factors and the only 1 targeted with RN22 cell line was cultured in DMEM with 10% FBS and approved therapies. However, in most cases, even though treat- P/S. All the cell cultures were maintained at 37 °C in 5% CO 2 ed with ocular pressure-lowering drugs, the disease keeps and they were grown in 60 and 100 mm tissue culture dishes progressing, and for this reason, neuroprotection is defined as (Beckton Dickinson, Franklin Lakes, NJ). a high priority for preventing blindness due to this condition [ 7]. In order to develop new therapies for prevention of brain PC12 Differentiation Assay damage [ 1–6], we screened combinatorial libraries of small chemicals in order to identify compounds that favor the sur- PC12 cell differentiation and survival was measured by plat- vival or differentiation of neuronal precursors and the survival ing cells onto collagen-coated 24-well plates and adding NGF of mature and immature neurons in the presence of stressors (100 ng/ml, [ 11 ]) or the small chemicals to the cultures at (including oxidative stress or trophic factor deprivation). We different concentrations (2-20-100 ng/ml and 2-20- also assessed the capacity of such compounds to promote the 50 μg/ml) (see additional details in Fig. S1 ). The number of survival and differentiation of myelin-forming cells. The differentiated cells with neurite processes greater than 2 cell screening included in vitro cell assays and in vivo models of bodies in length were counted after 5 days of treatment, neuroinflammation and neurodegeneration. We describe the counting 100 cells in 3 randomly selected fields in each well small chemical BN201 that displays an array of neuroprotec- (at least 300 cells were assessed at random in each experi- tive effects in neurons and myelin-forming cells, and is being ment) [ 11 ]. developed at present as a neuroprotective therapy for MS and optic neuritis (NCT03630497). In Vitro Oxidative Stress Survival Assays RN22 cells were plated in 24-well plates (20,000 cells/well) in Material and Methods DMEM alone and after allowing the cells to adhere for 3 days, and copper sulfate (CuSO 4, 150 μM) was added in the pres- Chemical Libraries ence or absence of NGF (100 ng/ml) or BN201 (1-10-50 ng/ml or 1-10 μg/ml [ 12 ]. After 24 h, cell viability was studied by Two different chemical libraries developed at the Institute of determining the amount of MTT (Sigma, St Louis, MI, USA) Medical Advanced Chemistry of Catalonia, CSIC, Barcelona, that was reduced to insoluble purple formazan. After remov- Spain (Prof Angel Messeguer), were tested: first, N- ing the medium, the water-insoluble formazan was solubilized alkylglycine trimers (peptoids), and second, cyclic in DMSO (Sigma) and the dissolved material was measured tetralkylammonium salts. The cyclic tetraalkylammonium on a spectrophotometer at a wavelength of 570 nm, salts library was composed of 66 master compounds (44 com- subtracting the background at 650 nm. pounds contained a 6-membered ring, whereas 22 contained a Human SH-SY5Y neuroblastoma cells were first differen- 7-membered ring) [ 8]. The peptoid (oligomers of N- tiated to a neuronal phenotype with retinoic acid (10 μM) for alkylglycine units) library consisted of controlled mixtures 6 days and they were then pretreated for 3 days with BN201 at constructed under the positional scanning format, and it was different doses (0.03, 0.1, 0.5, 1, 3, 5, 10, 20, and 100 μM) in composed by 5120 compounds [ 9, 10 ]. The lyophilized com- fresh medium, with or without K252a (200 nM). MPP + pounds were dissolved in H 2O with 5% DMSO for the in vitro (100 μM) or H 2O2 (100 μM) was then added after 30 min assays and were tested in controlled mixtures at 1 to 5 mg/ml. and the number of surviving cells was determined by quanti- fying the MTT staining 48 h later as described above [ 13 , 14 ]. Cell Lines Trophic Factor Deprivation In Vitro Assay All cell lines were obtained from the American Tissue Culture Collection (Manassas, VA, USA) and were tested and con- NSC-34 cells were seeded in 24-well poly-lysine-coated trolled for a number of expansion cycles. All in vitro experi- plates (30,000 cells/well) and preincubated for 24 h in ments were repeated twice. DMEM plus 10% FBS with various doses of BN201 (0.2, Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation 0.1, 2, 20, and 50 μg/ml), or with granulocyte-colony stimu- − mean RLU of vehicle control) / (mean RLU of EC80 con- lating factor (G-CSF) (2 μg/ml) or brain-derived trophic factor trol − mean RLU of vehicle control)). (BDNF) (20 ng/ml) as positive controls [ 15 ]. The medium was The CNS receptor assay is based in the binding to a radio- then removed and replaced with fresh DMEM without FBS, actively labeled CNS receptor. Compound binding was calcu- and after 48 h, cell viability was assayed by the MTT assay. lated as percentage inhibition of the binding of a radioactively labeled ligand specific for each target. Results showing an inhibition or stimulation higher than 50% are considered to In Vitro Remyelination Assays represent significant effects of the test compounds. The CETSA assay was conducted by Pelago Biosciences Purified retinal ganglion cells (4000/well) from P7 rats were Inc. (Solna, Sweden) in the SH-S5Y5 cell line. cultured in 96-well plates for 10 days in culture media in order to produce newly generated axons.
Load more

Recommended publications
  • Development of a Central Nervous System Axonal Myelination Assay for High Throughput Screening Karen D
    Lariosa‑Willingham et al. BMC Neurosci (2016) 17:16 DOI 10.1186/s12868-016-0250-2 BMC Neuroscience METHODOLOGY ARTICLE Open Access Development of a central nervous system axonal myelination assay for high throughput screening Karen D. Lariosa‑Willingham1,2, Elen S. Rosler1,3, Jay S. Tung1, Jason C. Dugas1,4, Tassie L. Collins1,5 and Dmitri Leonoudakis1,2* Abstract Background: Regeneration of new myelin is impaired in persistent multiple sclerosis (MS) lesions, leaving neurons unable to function properly and subject to further degeneration. Current MS therapies attempt to ameliorate auto‑ immune-mediated demyelination, but none directly promote the regeneration of lost and damaged myelin of the central nervous system (CNS). Development of new drugs that stimulate remyelination has been hampered by the inability to evaluate axonal myelination in a rapid CNS culture system. Results: We established a high throughput cell-based assay to identify compounds that promote myelination. Culture methods were developed for initiating myelination in vitro using primary embryonic rat cortical cells. We developed an immunofluorescent phenotypic image analysis method to quantify the morphological alignment of myelin characteristic of the initiation of myelination. Using γ-secretase inhibitors as promoters of myelination, the optimal growth, time course and compound treatment conditions were established in a 96 well plate format. We have characterized the cortical myelination assay by evaluating the cellular composition of the cultures and expres‑ sion of markers of differentiation over the time course of the assay. We have validated the assay scalability and consist‑ ency by screening the NIH clinical collection library of 727 compounds and identified ten compounds that promote myelination.
    [Show full text]
  • October 2004
    Myelin Repair Foundation Research Progress Summary October 2004 This summary outlines progress made by the Myelin Repair Foundation research team since June 2004 and includes findings from on-going research funded by other sources that members of the team found relevant to MRF research plan. Since the success of MRF is dependent on collaboration, rather than reporting on the progress of individual projects, this report describes progress towards MRF’s overall research goals and the contributions of various team members towards completing our understanding of critical aspects of myelination and how it is affected by the multiple sclerosis (MS) disease process. 1. Fundamental control of myelination: There are several MRF investigations focused on understanding the processes that control both myelination in development and remyelination after myelin loss due to inflammation and cell death: • Dr. Ben Barres’ lab has screened thousands of genes and identified 46 genes, specific to the myelination process, that show significantly higher or lower activity levels during developmental myelination than before or after the myelination process. In addition, Dr. Barres’ lab has demonstrated the timing of these changes during the developmental myelination process. The next step is to analyze the function of each of these 46 genes by artificially controlling its level of activity (expression) and observing the effect it has on myelin formation. Finding ways to artificially manipulate the expression of each gene is a formidable task. Although the functional analysis of each gene in this group is a significant project that may take several years to complete because of the large number of genes to be analyzed, the initial identification of these active genes is providing clues to other MRF researchers that will help prioritize which genes to evaluate first and which to ignore.
    [Show full text]
  • MRF Archive Compiled Research Summaries
    Myelin Repair Foundation Archived Research Summaries Summaries – 2008 Bailey, S. L., B. Schreiner, and S. D. Miller. 2008. CNS dendritic cells in inflammation and disease. In: Central Nervous System Diseases and Inflammation. (T. E. Lane, M. Carson, C. Bergmann and T. Wyss-Coray, eds.). Springer, New York, NY. Pp 263-275. http://www.springerlink.com/content/l17910144487u803/ Scientific Summary: CD11c+ DCs play a major role in both the initiation and progression of autoimmune inflammatory disease in the CNS. Since the CNS serves as the primary site where activation of pathogenic Th1/Th17 cells specific for endogenous myelin epitopes (i.e., epitope spreading), which play a critical role in driving progressive autoimmune disease, the current data suggests that the inflamed CNS can function as a neo-lymphoid organ. In support of this our recent unpublished data indicates that expression of genes encoding multiple receptor:ligand pairs involved in lymphoid organogenesis (including LTα1β2/LTβR, CXCL12/CXCR4, CSCL13/CXCR5, CCL21/CCR7, and CCL19/CCR7) are highly upregulated in the CNS. Further, mDCs are the main drivers of epitope spreading displaying the unique ability to acquire and present endogenous myelin peptides, to cluster specifically with naïve CD4+ T cells in the inflamed CNS and to polarize towards a Th17 phenotype when presenting endogenous myelin peptides. In conclusion, understanding the cues that determine DC signals to T cells will be crucial to understanding the fate of pathological (auto)immune inflammation in different tissues and diseases. Moreover, strategies targeting inhibition of the migration of myeloid DCs to the CNS may be an effective therapy for chronic immune-mediated CNS demyelinating diseases including MS.
    [Show full text]
  • Cerebellar Syndrome in a Man Treated with Natalizumab from the National Multiple Sclerosis Society Case Conference Proceedings
    DIAGNOSTIC AND TREATMENT CHALLENGES OPEN ACCESS Cerebellar syndrome in a man treated with natalizumab From the National Multiple Sclerosis Society Case Conference Proceedings David A. Lapides, MD, Prem P. Batchala, MD, Joseph H. Donahue, MD, Robert P. Lisak, MD,* Correspondence Ethan I. Meltzer, MD,§* Ram N. Narayan, MD,* Avi Nath, MD, PhD,* Teresa C. Frohman, MPAS, MSCSPA-C,‡* Dr. Goldman [email protected] ‡ † Kathleen Costello, MS, ANP-BC, * Myla D. Goldman, MD, MSc, Scott S. Zamvil, MD, PhD,* and or Dr. Zamvil Elliot M. Frohman, MD, PhD*† [email protected] or Dr. Frohman Neurol Neuroimmunol Neuroinflamm 2019;6:e546. doi:10.1212/NXI.0000000000000546 [email protected] A 57-year-old man with a medical history significant for bipolar disorder, depression, and anxiety presented in 2010 with bilateral lower extremity numbness progressing to perineal numbness and urinary retention. A “working” diagnosis of relapsing-remitting MS (RRMS) was supported by disseminated T2 hyperintensities on MRI investigations of the brain and spinal cord. Furthermore, CSF analysis revealed 4 unique oligoclonal bands not identified in blood. Initial treatment with IM interferon beta-1a exacerbated the patient’s depression, prompting discontinuation after only 6 weeks of injection therapy. He was then transitioned to daily subcutaneous glatiramer acetate, which was well tolerated and resulted in disease stabilization for approximately 12 months. He had a relapse in 2011 with symptoms corresponding to a new enhancing lesion in the thoracic spinal cord. The pronounced MS disease burden in the spinal cord, in conjunction with breakthrough disease activity while on glatiramer acetate, prompted the treating team to recommend in- tensification of disease-modifying therapy with natalizumab, which was administered IV every 4 weeks from 2011 to 2014 for a total of 33 treatments.
    [Show full text]
  • Neurimminfl2015006502 1..11
    Glatiramer acetate treatment negatively regulates type I interferon signaling Nicolas Molnarfi, PhD* ABSTRACT ’ Thomas Prod homme, Objective: Glatiramer acetate (GA; Copaxone), a disease-modifying therapy for multiple sclerosis (MS), PhD* promotes development of anti-inflammatory (M2, type II) monocytes that can direct differentiation of Ulf Schulze-Topphoff, regulatory T cells. We investigated the innate immune signaling pathways that participate in GA- PhD mediated M2 monocyte polarization. Collin M. Spencer, BS Methods: Monocytes were isolated from myeloid differentiation primary response gene 88 (MyD88)– Martin S. Weber, MD deficient, Toll-IL-1 receptor domain–containing adaptor inducing interferon (IFN)–b (TRIF)–deficient, IFN-a/b Juan C. Patarroyo, BS receptor subunit 1 (IFNAR1)–deficient, and wild-type (WT) mice and human peripheral blood. GA-treated Patrice H. Lalive, MD monocytes were stimulated with Toll-like receptor ligands, then evaluated for activation of kinases and Scott S. Zamvil, MD, transcription factors involved in innate immunity, and secretion of proinflammatory cytokines. GA-treated PhD mice were evaluated for cytokine secretion and susceptibility to experimental autoimmune encephalomyelitis. Results: GA-mediated inhibition of proinflammatory cytokine production by monocytes occurred inde- pendently of MyD88 and nuclear factor–kB, but was blocked by TRIF deficiency. Furthermore, GA did Correspondence to Dr. Zamvil: not provide clinical benefit in TRIF-deficient mice. GA inhibited activation of p38 mitogen-activated [email protected] protein kinase, an upstream regulator of activating transcription factor (ATF)–2, and c-Jun N-terminal kinase 1, which regulates IFN regulatory factor 3 (IRF3). Consequently, nuclear translocation of ATF-2 and IRF3, components of the IFN-b enhanceosome, was impaired.
    [Show full text]
  • Senior Investigator and Chief, Translational Neuroradiology Section Division of Neuroimmunology and Neurovirology National Insti
    Senior Investigator and Chief, Translational Neuroradiology Section Division of Neuroimmunology and Neurovirology National Institute of Neurological Disorders and Stroke, NIH Attending Neuroradiologist, NIH Clinical Center NAIMS/MAGNIMS ACTRIMS/ECTRIMS Teaching Course, October 25, 2017 Disclosures • Almost all of my work is funded by the NINDS Intramural Research Program. • Trainees in my lab have received support from the National MS Society, the American Brain Foundation, the Foundation of the Consortium of MS Centers, and the Conrad N. Hilton Foundation. • We have Cooperative Research and Development Agreements with the Myelin Repair Foundation and Vertex Pharmaceuticals. Not My Objective • To give a comprehensive overview of the complications of MS therapy. Main topics • PML • rebound • herpesviruses • other interesting reports Progressive Multifocal Leukoencephalopathy (PML) • Devastating brain infection caused by JC virus • Immunosuppression (now commonly iatrogenic) is the primary risk factor • ~25% mortality in the setting of MS • Best treatment: immune reconstitution Major risk factors for PML in MS • immunosuppression for > 2 years - especially natalizumab - also reported: fingolimod, dimethyl fumarate, rituximab • + serology for JCV (high JCV antibody index) • prior immunosuppressive therapy raises risk Up to 10% risk/year in year 6 if JCV index >1.5 PPMS... treated with natalizumab age 65 age 63 age 66 Infratentorial PML DWI age 65 65.5 ADC 66 CSF – 221,729 copies/ml of JCV DNA Plasma – 91 copies/ml of JCV DNA 66.1 Free Water
    [Show full text]
  • Demyelinating Disease Models of Central Nervous System
    Mechanisms of Immunopathology in Murine Models of Central Nervous System Demyelinating Disease This information is current as Anne M. Ercolini and Stephen D. Miller of September 29, 2021. J Immunol 2006; 176:3293-3298; ; doi: 10.4049/jimmunol.176.6.3293 http://www.jimmunol.org/content/176/6/3293 Downloaded from References This article cites 89 articles, 33 of which you can access for free at: http://www.jimmunol.org/content/176/6/3293.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 29, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. THE JOURNAL OF IMMUNOLOGY BRIEF REVIEWS Mechanisms of Immunopathology in Murine Models of Central Nervous System Demyelinating Disease1 Anne M. Ercolini and Stephen D. Miller2 Many disorders of the CNS, such as multiple sclerosis myelination reflect the diversity of clinical manifestations in (MS), are characterized by the loss of the myelin sheath humans.
    [Show full text]
  • BIOGRAPHICAL SKETCH Provide the Following Information for the Key Personnel and Other Significant Contributors in the Order Listed on Form Page 2
    BIOGRAPHICAL SKETCH Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. DO NOT EXCEED FOUR PAGES. NAME OF SPONSOR (CO-SPONSOR) POSITION TITLE Stephen D. Miller, Ph.D. Cong. John E. Porter Professor of Microbiology- eRA COMMONS USER NAME Immunology; Director, Immunobiology Center STEPHENMILLER EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) DEGREE INSTITUTION AND LOCATION YEAR(s) FIELD OF STUDY (if applicable) Penn State University, Univ. Park, PA B.S. 1969 MICROBIOLOGY Penn State University, Univ. Park, PA M.S. 1973 IMMUNOLOGY Penn State University, Univ. Park, PA PH.D. 1975 IMMUNOLOGY Univ. of Colorado Medical School POSTDOC 1975-78 CELL. IMMUNOLOGY A. Positions and Honors: POSITIONS: NIH Postdoctoral Research Fellow (with Henry N. Claman, M.D.), Univ. of Colorado Health Sci. Ctr., Denver, CO, 7/75-6/78 Instructor, Department of Medicine, Division of Clinical Immunology, Univ. of Colorado Health Sciences Ctr., Denver, CO, 7/78-6/80 Assistant Professor, Departments of Medicine and of Microbiology-Immunology, Univ. of Colorado Health Sciences Ctr., Denver, CO, 7/80-6/81 Department of Microbiology-Immunology, Northwestern Univ. Medical School, Chicago, IL, – Professor and Director of The Interdepartmental Immunobiology Center (9/92-Present); Congressman John E. Porter Professor (10/00-Present): Associate Professor (9/86-8/92); Assistant Professor (7/81-8/86) HONORS: USPHS Air Pollution Control Graduate Fellowship, 6/69-6/70 & 6/72-6/73 NIH Individual Post Doctoral Fellowship (AI-05593) 10/77-7/78 NIH Young Investigator Award (AI-14913) 8/78-7/81 Member - Honor Society of Phi Kappa Phi (1975); Am.
    [Show full text]
  • Background and Significance
    ROLE OF CHEMOKINES IN REGULATING OLIGODENDROCYTE DEVELOPMENT, ASTROGLIOSIS, AND DEMYELINATING DISEASES by AMBER E. KERSTETTER-FOGLE Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Thesis Advisor: Dr. Robert H. Miller Department of Neuroscience CASE WESTERN RESERVE UNIVERSITY January, 2010 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Amber E. Kerstetter-Fogle________________________ candidate for the _________Ph.D.__________degree *. (signed)______Jerry Silver________________________ (chair of the committee) ___________ Robert H. Miller______________________ __________ Ruth Siegel_________________________ ___________Richard Zigmond_____________________ ______________________________________________ ______________________________________________ (date) __October 26, 2009_____________________ *We also certify that written approval has been obtained for any proprietary material contained therein. Copyright © 2010 by Amber E. Kerstetter-Fogle All rights reserved This work is dedicated to my husband, Gary D. Fogle Jr. This is as much an accomplishment of his as it is mine. He has given up so much for me to get where I am today. I am thankful and greatful for the support and love he has given me all these years. TABLE OF CONTENTS List of Figures 3 Preface 5 Acknowledgements 6 List of Abbreviations 8 Abstract 10 Chapter 1 Background and Introduction I. Cellular composition of the nervous system 12 a. Astrocytes role in central nervous system function 13 b. Microglia: the primary immune defense in the CNS 15 c. Oligodendrocyte development and unique features 17 II. Inflammatory reaction and pathology in the CNS 21 a. Cytokines and their responsibility in inflammatory response 22 b. Chemokines and cytokines in development and disease 23 c. CXCR2 function and role in oligodendrocyte development and pathology 25 III.
    [Show full text]
  • Demyelination Disorders MS ALS Multiple Sclerosis
    Author - Editor: Professor of Medicine Desire’ Dubounet, D. Sc. L.P.C.C. 1 Contents ..................................................................................................... 1 Causes of Demyelination like ALS, Multiple Sclerosis etc ............................................................................. 4 Demyelinating disease of central nervous system, unspecified ............................................................. 10 Signs and Symptoms Consistent with Demyelinating Disease ................................................................... 11 Overview ................................................................................................................................................. 11 Visual ....................................................................................................................................................... 11 Motor ...................................................................................................................................................... 11 Sensory .................................................................................................................................................... 11 Cerebellar ................................................................................................................................................ 11 Genitourinary .......................................................................................................................................... 12 Neuropsychiatric ....................................................................................................................................
    [Show full text]
  • Making Myelin
    ANALYSIS FROM THE MAKERS OF AND REPRINT FROM JULY 28, 2011 Aberrant activation has been associated with neuronal degeneration Making myelin in Alzheimer’s disease (AD).2 Mi’s team showed that in mouse oligodendrocyte progenitor cells By Lauren Martz, Staff Writer (OPCs), small interfering RNA against Dr6 decreased caspase-3 Biogen Idec Inc. researchers have shown that knocking out tumor (Casp3; Cpp32) activation and cell death compared with control siRNA. necrosis factor receptor superfamily member 21 in rodents provides Both the survival and differentiation of OPCs are required for myelina- two angles of attack in multiple sclerosis: decreasing inflammation tion of CNS axons. and increasing remyelination.1 The latter ability could lead to repair Cultured OPCs from Dr6−/− mice had greater maturation and sur- of damaged myelin and consequent blocking of disease progression, vival than cells from wild-type mice. a key advantage over current MS drugs In rats already exhibiting symptoms of that mainly slow progression by lowering “These extensive, well- experimental autoimmune encephalomyelitis inflammation. designed studies suggest (EAE), intraperitoneal injection of an anti-Dr6 MS is an autoimmune disease character- that an anti-DR6 antibody decreased disease severity and increased the ized by destruction of the myelin sheath on has a direct effect on the number of remyelinated axons in EAE lesions axons that leads to a broad spectrum of neu- survival and differentiation compared with injection of a control antibody. rological symptoms. Until recently, the dis- of DR6-positive immature The treatment also decreased infiltration of T ease was treated with immune-suppressing oligodendrocytes and cells into the spinal column, suggesting that in therapeutics, including Avonex interferon promotes remyelination addition to remyelinating axons, DR6 antago- beta-1a from Biogen Idec, Rebif inter- nism also might decrease inflammation.
    [Show full text]
  • Evaluating the Safety of B-Interferons in MS a Series of Nested Case-Control Studies
    Evaluating the safety of b-interferons in MS A series of nested case-control studies Hilda J.I. de Jong, PhD ABSTRACT Elaine Kingwell, PhD Objective: To examine the association between interferon-b (IFN-b) and potential adverse events Afsaneh Shirani, MD using population-based health administrative data in British Columbia, Canada. Jan Willem Cohen Methods: Patients with relapsing-remitting multiple sclerosis (RRMS) who were registered at Tervaert, PhD, MD a British Columbia Multiple Sclerosis Clinic (1995–2004) were eligible for inclusion and were Raymond Hupperts, followed up until death, absence from British Columbia, exposure to a non–IFN-b disease- PhD, MD modifying drug, or December 31, 2008. Incidence rates were estimated for each potential Yinshan Zhao, PhD adverse event (selected a priori and defined with ICD-9/10 diagnosis codes from physician and Feng Zhu, MSc hospital claims). A nested case-control study was conducted to assess the odds of previous IFN-b Charity Evans, PhD exposure for each potential adverse event with at least 30 cases. Cases were matched by age Mia L. van der Kop, MSc (65 years), sex, and year of cohort entry, with up to 20 randomly selected (by incidence density Anthony Traboulsee, MD sampling) controls. Odds ratios (ORs) with 95% confidence intervals (95% CIs) were estimated Paul Gustafson, PhD with conditional logistic regression adjusted for age at cohort entry. John Petkau, PhD b Ruth Ann Marrie, PhD, Results: Of the 2,485 eligible patients, 77.9% were women, and 1,031 were treated with IFN- MD during follow-up. From the incidence analyses, 27 of the 47 potential adverse events had at least – Helen Tremlett, PhD 30 cases.
    [Show full text]